Literature DB >> 18772042

Serotonin receptors as potential targets for modulation of nicotine use and dependence.

Paul J Fletcher1, Anh Dzung Lê, Guy A Higgins.   

Abstract

Nicotine use carries considerable health risks and plays a major role in a variety of diseases. Current pharmacological treatments to aid in smoking cessation include nicotine-replacement therapy and non-nicotinic strategies such as bupropion and varenicline. While these treatments benefit some individuals there is still a need for better and more effective treatment strategies. Nicotine is the major psychoactive substance in tobacco. Some behavioural effects of nicotine, including its reinforcing efficacy result in part from activation of mesolimbic dopamine neurons. Modulation of dopamine function is one potential treatment strategy that could treat nicotine dependence. Serotonergic neurons modulate the functioning of dopamine neurons in a complex fashion. Much of this complexity arises from the fact that serotonin (5-HT) exerts its effects through multiple receptor subtypes, some of which even act in apparent functional opposition to each other. This article reviews evidence, primarily from animal experiments, using behavioural procedures relevant to nicotine use on the potential for 5-HT receptors as targets for treating nicotine dependence. The 5-HT(1A, 2A, 2C, 3, 4, 6) receptor subtypes have received most experimental attention, with the 5-HT(1A) and 5-HT(2C) receptors being the best studied. Several studies have now shown that 5-HT(1A) receptor antagonists alleviate some of the behavioural signs induced by nicotine withdrawal. Electrophysiological and neurochemical studies show that stimulation of 5-HT(2C) receptors reduces the function of the mesolimbic dopamine pathway. 5-HT(2C) receptor agonists block the stimulatory action of nicotine on midbrain dopamine function. They also reduce several behavioural effects of nicotine including its discriminative stimulus properties and reinforcing effects. Although more work remains to be done, 5-HT(2C) receptor agonists perhaps hold the most promise as potential therapies for smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18772042     DOI: 10.1016/S0079-6123(08)00918-7

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  21 in total

1.  Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Maryka Quik; Archana Mallela; Jason Ly; Danhui Zhang
Journal:  Mov Disord       Date:  2013-07-08       Impact factor: 10.338

2.  Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists.

Authors:  Roberta Galeazzi; Luca Massaccesi; Francesco Piva; Giovanni Principato; Emilioano Laudadio
Journal:  J Mol Model       Date:  2014-02-22       Impact factor: 1.810

3.  Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice.

Authors:  Gongliang Zhang; Xian Wu; Yong-Mei Zhang; Huan Liu; Qin Jiang; Gang Pang; Xinrong Tao; Liuyi Dong; Robert W Stackman
Journal:  Neuropharmacology       Date:  2015-12-03       Impact factor: 5.250

4.  The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control.

Authors:  Guy A Higgins; Leo B Silenieks; Anne Rossmann; Zoe Rizos; Kevin Noble; Ashlie D Soko; Paul J Fletcher
Journal:  Neuropsychopharmacology       Date:  2011-12-21       Impact factor: 7.853

Review 5.  The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders.

Authors:  Catharine A Winstanley
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Evidence for a role of 5-HT2C receptors in the motor aspects of performance, but not the efficacy of food reinforcers, in a progressive ratio schedule.

Authors:  G Bezzina; S Body; T H C Cheung; C L Hampson; C M Bradshaw; J C Glennon; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  2014-08-19       Impact factor: 4.530

Review 7.  Contributions of serotonin in addiction vulnerability.

Authors:  L G Kirby; F D Zeeb; C A Winstanley
Journal:  Neuropharmacology       Date:  2011-04-03       Impact factor: 5.250

8.  Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.

Authors:  Maryka Quik; Archana Mallela; Matthew Chin; J Michael McIntosh; Xiomara A Perez; Tanuja Bordia
Journal:  Neurobiol Dis       Date:  2012-09-23       Impact factor: 5.996

9.  Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation.

Authors:  Ju Wang; Ming D Li
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

10.  ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Danhui Zhang; Tanuja Bordia; Matthew McGregor; J Michael McIntosh; Michael W Decker; Maryka Quik
Journal:  Mov Disord       Date:  2014-02-11       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.